78 related articles for article (PubMed ID: 9135470)
1. Usefulness of iron colloid-enhanced MRI in differentiating experimental hepatocellular carcinoma from hyperplastic nodules in rats: analysis by microautoradiography.
Suto Y; Kodama F
Br J Radiol; 1996 Dec; 69(828):1139-44. PubMed ID: 9135470
[TBL] [Abstract][Full Text] [Related]
2. Correlation between chondroitin sulfate iron colloid-enhanced MR imaging and the histological grade of hepatocellular carcinoma.
Suto Y; Kodama F; Kamba M; Ohta Y
Acta Radiol; 1995 Jan; 36(1):102-5. PubMed ID: 7833161
[TBL] [Abstract][Full Text] [Related]
3. Chondroitin sulfate iron colloid as MR contrast agent in differentiation between hepatocellular carcinoma and adenomatous hyperplasia.
Suto Y; Kato T; Matsuo T; Kamba M; Shimatani Y; Ohuchi Y; Nakamura K; Ohta Y
Acta Radiol; 1993 May; 34(3):226-9. PubMed ID: 8387803
[TBL] [Abstract][Full Text] [Related]
4. Chondroitin sulfate iron colloid-enhanced MR imaging in patients with hepatocellular carcinoma. Comparison with CT during arterial portography.
Kamba M; Suto Y; Kato T
Acta Radiol; 1994 Nov; 35(6):570-5. PubMed ID: 7946680
[TBL] [Abstract][Full Text] [Related]
5. Optimum conditions for iron colloid enhanced fast spin echo imaging in hepatocellular carcinoma.
Sugihara S; Suto Y; Yoshida K
Br J Radiol; 1997 Aug; 70(836):791-7. PubMed ID: 9486042
[TBL] [Abstract][Full Text] [Related]
6. Time-course changes of contrast enhancement in iron colloid enhanced MRI in patients with hepatocellular carcinoma.
Suto Y; Ametani M; Kamba M; Sugihara S
Br J Radiol; 1996 Mar; 69(819):201-5. PubMed ID: 8800862
[TBL] [Abstract][Full Text] [Related]
7. A study of chondroitin sulfate iron colloid as a liver specific MR contrast agent.
Hussain MZ; Ohtomo K; Kachi K; Uchiyama G; Itai Y
Radiat Med; 1994; 12(1):1-5. PubMed ID: 8016397
[TBL] [Abstract][Full Text] [Related]
8. Dual contrast magnetic resonance imaging with combined use of positive and negative contrast agent in human hepatocellular carcinoma.
Suto Y; Shimatani Y
Br J Radiol; 1995 Feb; 68(806):116-20. PubMed ID: 7735739
[TBL] [Abstract][Full Text] [Related]
9. Chondroitin sulfate iron colloid as an MR contrast agent for the hepatic reticuloendothelial system.
Kato T; Suto Y; Matsuo T
J Comput Assist Tomogr; 1993; 17(4):603-8. PubMed ID: 8392526
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma exhibiting a concentric structure of different histologic grades: evaluation by chondroitin sulfate iron colloid-enhanced MR imaging.
Kamba M; Suto Y; Kodama F; Ohta Y; Kobayashi J; Horie Y; Kawasaki H
J Magn Reson Imaging; 1996; 6(2):406-8. PubMed ID: 8859586
[TBL] [Abstract][Full Text] [Related]
11. [The Iron Content of Hepatocellular Carcinoma Associated Nodules: Study of Histopathology and MR Imaging].
Liu D; Song B; Huang ZX; Wu B; Tang HH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 May; 47(3):376-81. PubMed ID: 27468484
[TBL] [Abstract][Full Text] [Related]
12. [Superparamagnetic iron oxide-enhanced magnetic resonance imaging of hepatocellular carcinoma in rats].
Liu X; Xu YK; Huang QL; Wu YK
Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1061-5. PubMed ID: 12480574
[TBL] [Abstract][Full Text] [Related]
13. Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver.
Tanaka M; Nakashima O; Wada Y; Kage M; Kojiro M
Hepatology; 1996 Oct; 24(4):807-12. PubMed ID: 8855180
[TBL] [Abstract][Full Text] [Related]
14. [Iron oxide-enhanced MR imaging of hepatocellular carcinoma of woodchuck].
Ohtomo K; Shiga J; Sasaki Y; Itai Y
Nihon Igaku Hoshasen Gakkai Zasshi; 1991 Apr; 51(4):433-5. PubMed ID: 1648709
[TBL] [Abstract][Full Text] [Related]
15. Imaging of benign hypervascular hepatocellular nodules in alcoholic liver cirrhosis: differentiation from hypervascular hepatocellular carcinoma.
Kobayashi S; Matsui O; Kamura T; Yamamoto S; Yoneda N; Gabata T; Terayama N; Sanada J
J Comput Assist Tomogr; 2007; 31(4):557-63. PubMed ID: 17882031
[TBL] [Abstract][Full Text] [Related]
16. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
17. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
[TBL] [Abstract][Full Text] [Related]
18. Characterization of hepatic lesions (≤ 30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging.
Takahashi M; Maruyama H; Shimada T; Kamezaki H; Sekimoto T; Kanai F; Yokosuka O
Eur J Radiol; 2013 Jan; 82(1):75-84. PubMed ID: 23116806
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
20. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging.
Gatto A; De Gaetano AM; Giuga M; Ciresa M; Siciliani L; Miele L; Riccardi L; Pizzolante F; Rapaccini GL; Gasbarrini A; Giuliante F; Vecchio FM; Pompili M; Bonomo L
Abdom Imaging; 2013 Aug; 38(4):736-44. PubMed ID: 22986351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
